Results 191 to 200 of about 62,672 (281)

Comment on: Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Rani T, Mandal R, Bandyopadhyay A.
europepmc   +1 more source

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5163-5173, June 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used for the treatment of type 2 diabetes, yet their downstream consequences in routine clinical practice remain incompletely characterized.
Yazan Alhamdan, Jason C. Hsu, Christine Y. Lu   +2 more
wiley   +1 more source

Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. [PDF]

Arthritis Rheumatol
Hlavaty A, Dari L, Cracowski JL, Roustit M, Khouri C.   +4 more
europepmc   +1 more source

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1385-1396, May 2026.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman, Mathieu Félices, Bhaskar Pandurangavittal, Sanman Ghorpade, Caroline Easterbrook, Marcin Zabielski, Oscar Della Pasqua   +6 more
wiley   +1 more source

Incidence and trends of adverse drug reactions during seasonal malaria chemoprevention among children: evidence from Ghana's pharmacovigilance database, 2015-2023. [PDF]

Malar J
Otoo BAF, Opoku-Mireku M, Seaneke SK, Darko DM, Sabblah GT, Bonful HA.   +5 more
europepmc   +1 more source

Redefining the role of the transfusion medicine physician in the era of advanced cellular therapies

Transfusion, EarlyView.
Eric A. Gehrie, Kevin J. Land
wiley   +1 more source

Trimethoprim/Sulfamethoxazole‐Induced Systemic Toxic Epidermal Necrolysis Syndrome: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Trimethoprim/sulfamethoxazole can induce life‐threatening toxic epidermal necrolysis. Early recognition, immediate drug cessation, and multidisciplinary supportive care are critical. Even with aggressive therapy, mortality remains high, and SCORTEN score aids in prognostication.
Qing Wang, Litong Chen, Wen Ye
wiley   +1 more source

Adverse drug reaction reporting and monitoring: A review of global practices. [PDF]

Bioinformation
Mohsin N, Alyami AM, Al Shermah IM, Al Shermah AM, Alharthi KM, Alyami TM, Almakrami HA, Mohammed Muqmish HH, Ali Sarrar IJ.   +8 more
europepmc   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1382-1390, May 2026.
Genetic variation has a significant impact on patients' response to medicines. Variations in important pharmacogenes have been evaluated in several studies and consequently led to international guidelines from clinical pharmacogenomics consortia. However, there are limited examples of these being implemented across the African continent despite the ...
Janine Scholefield, Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Collen Masimirembwa   +5 more
wiley   +1 more source